Nanoprecipitation is more efficient than emulsion solvent evaporation method to encapsulate cucurbitacin I in PLGA nanoparticles

被引:93
作者
Alshamsan, Aws [1 ]
机构
[1] King Saud Univ, Coll Pharm, Dept Pharmaceut, Nanomed Res Unit, Riyadh, Saudi Arabia
关键词
PLGA; Cucurbitacin I; Nanoprecipitation; Nanoparticles; Emulsion solvent evaporation; DRUG-DELIVERY; JSI-124;
D O I
10.1016/j.jsps.2013.12.002
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
Cucurbitacin I is a hydrophobic molecule that exerts a degree of polarity, which is expected to complicate its loading in PLGA nanoparticles by the classical emulsion solvent evaporation technique. In the current study, variants of emulsion solvent evaporation method were used to prepare PLGA nanoparticles of cucurbitacin: CI-NP1 (single emulsion starting with 1000 mu g drug), CI-NP2 (double emulsion starting with 250 mu g drug), and CI-NP3 (double emulsion starting with 500 mu g drug). On the other hand, CI-NP4 was prepared by nanoprecipitation (starting with 1000 mu g drug). In CI-NP1, cucurbitacin I encapsulation efficiency (EE) was 1.29%. The employment of double emulsion, in CI-NP2 and CI-NP3, increased cucurbitacin I EE to 4.8% and 7.96%, respectively. Nanoprecipitation significantly increased the EE of cucurbitacin I to 48.79% in CI-NP4. It is likely that cucurbitacin I escapes with the organic solvent after the emulsification step to the aqueous phase leading to ineffective entrapment in the polymeric matrix. Avoiding emulsification seems efficient in increasing cucurbitacin I disposition in the instantly-precipitating NPs. Therefore, nanoprecipitation method increases cucurbitacin I entrapment in PLGA NPs and possibly other water-insoluble polar drugs. (C) 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.
引用
收藏
页码:219 / 222
页数:4
相关论文
共 9 条
[1]
PLGA nanoparticles in drug delivery: The state of the art [J].
Bala, I ;
Hariharan, S ;
Kumar, MNVR .
CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS, 2004, 21 (05) :387-422
[2]
Nanoprecipitation versus emulsion-based techniques for the encapsulation of proteins into biodegradable nanoparticles and process-related stability issues [J].
Bilati, U ;
Allémann, E ;
Doelker, E .
AAPS PHARMSCITECH, 2005, 6 (04)
[3]
Blaskovich MA, 2003, CANCER RES, V63, P1270
[4]
The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices [J].
Jain, RA .
BIOMATERIALS, 2000, 21 (23) :2475-2490
[5]
Targeting Stat3 in cancer therapy [J].
Jing, N ;
Tweardy, DJ .
ANTI-CANCER DRUGS, 2005, 16 (06) :601-607
[6]
Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier [J].
Makadia, Hirenkumar K. ;
Siegel, Steven J. .
POLYMERS, 2011, 3 (03) :1377-1397
[7]
Development of a Poly(D,L-lactic-co-glycolic acid) Nanoparticle Formulation of STAT3 Inhibitor JS']JSI-124: Implication for Cancer Immunotherapy [J].
Molavi, Leila ;
Mahmud, Abdullah ;
Hamdy, Samar ;
Hung, Ryan W. ;
Lai, Raymond ;
Samuel, John ;
Lavasanifar, Afsaneh .
MOLECULAR PHARMACEUTICS, 2010, 7 (02) :364-374
[8]
Molavi O, 2006, J PHARM PHARM SCI, V9, P158
[9]
Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives [J].
Mundargi, Raghavendra C. ;
Babu, V. Ramesh ;
Rangaswamy, Vidhya ;
Patel, Pradip ;
Aminabhavi, Tejraj M. .
JOURNAL OF CONTROLLED RELEASE, 2008, 125 (03) :193-209